Co-Authors
This is a "connection" page, showing publications co-authored by Jérémie Guedj and Xavier de Lamballerie.
Connection Strength
1.887
-
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med. 2018 03; 15(3):e1002535.
Score: 0.761
-
SARS-CoV-2 viral dynamics in non-human primates. PLoS Comput Biol. 2021 03; 17(3):e1008785.
Score: 0.234
-
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. CPT Pharmacometrics Syst Pharmacol. 2020 09; 9(9):509-514.
Score: 0.224
-
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. Clin Pharmacol Ther. 2020 08; 108(2):188.
Score: 0.221
-
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun. 2018 10 01; 9(1):4013.
Score: 0.197
-
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun. 2021 03 19; 12(1):1735.
Score: 0.058
-
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020 09; 585(7826):584-587.
Score: 0.056
-
Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses". Antimicrob Agents Chemother. 2018 01; 62(1).
Score: 0.047
-
Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):8847-8852.
Score: 0.045
-
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 02; 11(2):e0005389.
Score: 0.044